VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalones future development related to COVID-19, will focus on the prevention and treatment of Post COVID-19 Conditions. The companys new focus on patients with Post COVID-19 Conditions (PCC), colloquially known as long-COVID, as opposed to hospitalized COVID-19 patients, reflects the compelling opportunity for apabetalone to benefit long-COVID patients along with guidance from the US Food and Drug Administration.
A Media Snippet accompanying this announcement is available by clicking on the image or link below:
For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company. The video is available for viewing on InvestmentPitch.com and on YouTube. If these links are not enabled, please visit http://www.InvestmentPitch.com and enter Resverlogix in the search box.
Following the recent FDA meeting, Dr. Michael Sweeney, Senior VP, Clinical Development for Resverlogix, stated: We are grateful to the FDA for the feedback and suggestions provided in our recent Type C meeting, and we look forward to continuing to work with regulators in our evaluation of apabetalones safety and efficacy in treating Post COVID-19 Conditions.
A recent estimate from the CDC suggests that as many as one-in-three US adults may experience long-COVID after contracting COVID-19. Vaccination against COVID-19 helps reduce the risk of long-COVID, but only by as little as 15%, according to a recent study of more than 13 million people.
Dr. Michael Sweeney, added: Patients around the world are dealing with persistent COVID-19 symptoms, often lasting weeks and months after their initial infections. There are currently few available treatment options for this group of people, and we feel that apabetalone has great potential to help them. We know that individuals who contract COVID-19 are at greater risk of negative cardiovascular outcomes, and we have seen the cardioprotective benefit of apabetalone in other high-risk populations.
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company and the world leader in epigenetics, or gene regulation, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes.
Apabetalone (RVX-208), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease progression by regulating the expression of disease-causing genes. Due to the extensive role for BET proteins in the human body, apabetalone, can simultaneously target multiple disease-related biological processes while maintaining a well-described safety profile leading to a new way to treat chronic disease.
Apabetalone received Breakthrough Therapy Designation from the FDA and is the only drug of its class with an established safety record in human clinical trials, with well over 4200 patient-years of safety data across 10 clinical trials. Studies published in prestigious scientific journals, including Cell, demonstrate that apabetalone has the potential to act against COVID-19 with a unique dual-mechanism: first by preventing viruses from entering the cells and replicating; and second by averting excessive inflammatory reactions that can cause severe and lasting organ damage.
The investigational treatment could potentially reduce the severity and duration of post COVID-19 conditions. Apabetalones unique dual-mechanism also means that it has the potential to show efficacy against new COVID-19 variants and may even help fight other viruses. The company is finalizing the Phase 3 study protocol of apabetalone in PCC and plans to launch the trial in the first half of 2023, subject to all necessary regulatory and other applicable approvals and securing the necessary resources.
Resverlogix has partnered with EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid global commercialization of apabetalone for COVID-19. EVERSANA is currently leading clinical outreach and advocacy for apabetalone.
The shares are trading at $0.21. For more information. please visit companys website, http://www.resverlogix.com, or contact the company at 403-254-9252 or by email at ir@resverlogix.com.
Disclaimer
The information in this InvestmentPitch Media Ltd video is for the viewers information only. Resverlogix has paid a fee not exceeding $2,000 in cash to have its current news release produced in video format. The corporate information is based on information that is publicly available. Any information provided by InvestmentPitch Media Ltd., through its media services is not to be construed as a recommendation or suggestion or offer to buy or sell securities but is provided solely as an informational media service. InvestmentPitch Media Ltd makes no warranties or undertakings as to the accuracy or completeness of this information. All due diligence should be done by the viewer or their financial advisor. Investing in securities is speculative and carries risk.
About InvestmentPitch Media
InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a companys story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.
See the article here:
InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone's Future Development for the Prevention and Treatment of Post COVID-19...
- The Role of Epigenetics and Contributing Impact of Stress, Multigenerational, and Developmental Factors in Opiate ... - Cureus - February 8th, 2024
- About Epigenetics | Johns Hopkins Institute of Genetic Medicine - November 16th, 2023
- What is Epigenetics? - Bruce H. Lipton, PhD - January 4th, 2023
- Why Epigenetics Contradicts Evolutionary Theory | Evolution News - December 18th, 2022
- Epigenetics in Psychology | Noba - November 24th, 2022
- Epigenetics: Definition, Mechanisms and Clinical Perspective - November 24th, 2022
- Researchers Find that Moms Pass On Additional Epigenetic Information To Their Children - WhatIsEpigenetics.com - October 13th, 2022
- Prestigious award advances OHSU research on impact of drug use over generations - OHSU News - October 13th, 2022
- Hoylake doctor launches test that detects diseases before they appear - Wirral Globe - October 13th, 2022
- Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics - Yahoo Finance - October 13th, 2022
- Understanding the Epigenetics of Childhood Trauma - Psych Central - October 4th, 2022
- Epigenetic therapy promotes spinal cord regeneration in mice following injury - RegMedNet - October 4th, 2022
- ORYZON to Give Updates on Corporate Progress in October - Yahoo Finance - October 4th, 2022
- Cardio Diagnostics To Sponsor, Participate in the American Heart Association's 2022 Metro Chicago Heart Walk - Yahoo Finance - September 16th, 2022
- Book review: Daughters and the stories they carry - Yahoo News - September 16th, 2022
- Inherent Biosciences raises funding to expand fertility care though epigenetics - VatorNews - September 8th, 2022
- 10 wellness retreat trends to know about - Cond Nast Traveller - September 8th, 2022
- Spotlight: Women in Science: Dr. Judith Kassis on Pursuing the Unexpected - National Institute of Child Health and Human Development - September 8th, 2022
- Epigenetic Information Passed On to Offspring More Frequently Than Once Thought - Technology Networks - August 22nd, 2022
- New discovery shows you may inherit more from your mom than you think - EastMojo - August 22nd, 2022
- New Technology to Understand Cell Types and How Diseases Develop - Yale University - August 22nd, 2022
- Research Roundup: Fat Cell Hormone Slows Liver Tumor Growth and More Research News - BioSpace - August 22nd, 2022
- De-extinction? Plans to revive Tasmanian tiger triggers... - The American Bazaar - August 22nd, 2022
- Epigenetics in Health and Disease - PubMed - August 14th, 2022
- Clinical Epigenetics | Home page - August 14th, 2022
- Efficacy of Neoadjuvant Immunotherapy on Breast Cancer is Independent of Race - Pharmacy Times - August 14th, 2022
- Your True Age Might Not Be Your Birthdate And Thats Good News - Goalcast - August 14th, 2022
- Epigenetics Market is Predicted to Hit $6460.5 Million Value by 2030, says P&S Intelligence - PR Newswire UK - July 27th, 2022
- ORYZON Collaborates with the CMT Research Foundation in the US - Yahoo Finance - July 27th, 2022
- What is schizophrenia? Common myths and misconceptions around the mental illness - The Mirror - July 27th, 2022
- What gene changes and blood could tell us about the opioid crisis - UCI News - July 19th, 2022
- Epigenetics Is The Key To Treating Complex Diseases; Dr. Nirmalya Saha Is Using It To Unlock Cancer Treatment And More - EconoTimes - July 19th, 2022
- Heatstroke stresses the body years after the original heat illness - University of Florida - July 19th, 2022
- Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma... - July 19th, 2022
- Genetics proposes, epigenetics disposes: how our approach to human health changes in the 21st century and how CRISPR-Cas is involved - Digital Journal - June 22nd, 2022
- Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology... - June 22nd, 2022
- The relationship between P16INK4A and TP53 promoter methylation and the risk and prognosis in patients with oesophageal cancer in Thailand |... - June 22nd, 2022
- Omega Therapeutics (OMGA) Research Analysts' Weekly Ratings Changes - Defense World - June 13th, 2022
- Introducing Cantata Bio, Inventive Multimodal Solutions for Accelerating Genome-based R&D - Business Wire - June 13th, 2022
- Plant biologist nominated for prestigious early career award - University of Georgia - June 13th, 2022
- Julee Cruise's Career: How and where to watch Twin Peaks and all her TV appearances - Bolavip US - June 13th, 2022
- Hitting the Pro Race Track: Onovi Health Adds Marko Radiic, Professional Race Car Driver & Entrepreneur, as a Brand Ambassador - PR Newswire - June 13th, 2022
- Epigenetics: Definition & Examples | Live Science - June 4th, 2022
- Genetics and Epigenetics of Addiction DrugFacts | National Institute on ... - June 4th, 2022
- Epigenetics Market is Growing Rapidly with Recent Demand, Trends, Development, Revenue and Forecast to 2029 The Greater Binghamton Business Journal -... - June 4th, 2022
- Epigenetics at the Intersection of COVID-19 Risk and Environmental Chemical Exposures - DocWire News - June 4th, 2022
- Global Epigenetics Instrument Market 2022 Covid 19 Impact on Top countries data |Illumina, Thermo Fisher, Diagenode The Greater Binghamton Business... - June 4th, 2022
- Global Biomarkers Market Outlook & Forecast 2022-2027: Increase In Number of Pipeline Biomarkers & Rising Adoption of Biomarkers In Disease... - June 4th, 2022
- Many African Americans face unresolved trauma of racism and enslavement; It's affecting their health - ideastream - June 4th, 2022
- Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial - BioSpace - May 15th, 2022
- Gene edited rats cured of anxiety and alcoholism | SYFY WIRE - Syfy - May 15th, 2022
- Dreams on Fire sheds light on epigenetics, collective trauma of genocide traveling through generations - Armenian Weekly - May 2nd, 2022
- NEAR science: good for what ails stressed communities - NUjournal - May 2nd, 2022
- Digital biomarkers - An Emerging tool in precision Medicines. The Biomarkers Market to Reach $86 Billion by 2027 - Arizton - Yahoo Finance - May 2nd, 2022
- Sprint Bioscience's NIMA program is focused on the target protein NNMT and will be launched at the BIO International convention - Marketscreener.com - May 2nd, 2022
- Post-Doctoral Associate in the Center for Genomics and Systems Biology job with NEW YORK UNIVERSITY ABU DHABI | 291713 - Times Higher Education - May 2nd, 2022
- Womb with a View: On the Science of Maternal Effects - lareviewofbooks - April 19th, 2022
- Molecular Biology Enzymes, Kits & Reagents Market likely to bring in approximately US$ 22000 Million revenues by 2026-end Political Beef -... - April 19th, 2022
- Type 2 diabetes on the rise among Wisconsin children - Iron Mountain Daily News - April 19th, 2022
- January 2022: Exposures, diverse populations, and epigenetics merge in grantee's lab - Environmental Factor Newsletter - January 5th, 2022
- Research Roundup: Why mRNA Vaccines are So Good Against Severe COVID-19 and More - BioSpace - January 5th, 2022
- Epigenetics - Genome.gov - December 24th, 2021
- Genetics, Epigenetics, and Cancer: What Data Are We Missing? - AJMC.com Managed Markets Network - December 24th, 2021
- Can epigenetics help solve the puzzle between concomitant cardiovascular injury and severity of COVID-19? - DocWire News - December 24th, 2021
- Genomics Market Revenue to Cross US$ 49996.15 by 2027: The Insight Partners - Digital Journal - December 24th, 2021
- Hydra regrow their heads and live forever due to epigenetics - Cosmos Magazine - December 10th, 2021
- Epigenetics Market to Garner US$ 2611.57 MN, Globally, by 2025 at 13.6% CAGR: The Insight Partners - Digital Journal - December 10th, 2021
- Research Associate or Research Assistant in Medical and Molecular Genetics job with KINGS COLLEGE LONDON | 274309 - Times Higher Education (THE) - December 10th, 2021
- Newpath Commits $350 Million to Fund the Next Good Things in the Life Sciences - BioSpace - December 10th, 2021
- Wind Turbine Market Development Overview And Analysis Till 2030- Market.Biz - Digital Journal - December 10th, 2021
- Cancer Testing Product Market to Witness Growth Acceleration | Epigenetics Ag, Techlab, Positive Bioscience Energy Siren - Energy Siren - November 22nd, 2021
- How can students make the best of their anxiety? - The Medium - November 22nd, 2021
- Epigenetic Study Links Smoke Exposure in Early Life to Advanced Aging - WhatIsEpigenetics.com - October 28th, 2021
- Salarius Pharmaceuticals (SLRX) is Developing a Novel LSD1 Inhibitor, Positioning it as a Significant Mover in Epigenetics-Based Cancer Therapies -... - October 28th, 2021
- Epigenetics-Based Kits Market To Witness High Growth In Near Future IMIESA - IMIESA - October 28th, 2021
- Epigenetics Diagnostic Market to Witness Growth Acceleration | Qiagen, Abcam plc, Novartis AG, Thermo Fisher Scientific IMIESA - IMIESA - October 28th, 2021
- LXRepair, Gustave Roussy Ink Research Partnership in Personalized Radiotherapy - Precision Oncology News - October 28th, 2021
- Van Andel Institute, Maine Medical Center Research Institute scientists earn $9.6 million Transformative Research Award from National Institutes of... - October 5th, 2021
- Epigenetics could reveal if you had a 'vanishing twin' - Popular Science - October 5th, 2021
- Epigenetics: Conducting The Symphony Of Genetics - Forbes - August 5th, 2021